Suppr超能文献

中国在治疗儿童肝母细胞瘤方面的多学科努力。

Multidisciplinary effort in treating children with hepatoblastoma in China.

作者信息

Yuan Xiao-Jun, Wang Huan-Min, Jiang Hui, Tang Meng-Jie, Li Zhang-Lin, Zou Xiang, Fang Yong-Jun, Pan Ci, Tou Jin-Fa, Zhang Ke-Ren, Liu Xiang, Li Wei-Song, Li Yang, Lu Jun, Wu Ye-Ming

机构信息

Department of Pediatric Hematology/Oncology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.

Department of Surgical Oncology, Beijing Children's Hospital Affiliated to Capital Medical University, China.

出版信息

Cancer Lett. 2016 May 28;375(1):39-46. doi: 10.1016/j.canlet.2016.02.051. Epub 2016 Mar 2.

Abstract

The purpose of this study is to report the first nationwide protocol (Wuhan Protocol) developed by Chinese Children's Cancer Group and the results of multidisciplinary effort in treating hepatoblastoma. In this study, we reported the final analysis, which includes 153 hepatoblastoma patients in 13 hospitals from January 2006 to December 2013. The 6-year overall survival and event-free survival rates were 83.3 ± 3.1% and 71.0 ± 3.7%, respectively, in this cohort. The univariate analysis revealed that female (P = 0.027), under 5 years of age (P = 0.039), complete surgical resection (P = 0.000), no metastases (P = 0.000), and delayed surgery following neoadjuvant chemotherapy (P = 0.000) had better prognosis. In multivariate analysis, male, 5 years of age or above, stage PRETEXT III or IV, and incomplete surgical resection were among the some adverse factors contributing to poor prognosis. The preliminary results from this study showed that patients who underwent treatment following Wuhan Protocol had similar OS and EFS rates compared to those in developed countries. However, the protocol remains to be further optimized in standardizing surgical resection (including liver transplantation), refining risk stratification and risk-based chemotherapy.

摘要

本研究旨在报告中国儿童癌症协作组制定的首个全国性方案(武汉方案)以及多学科协作治疗肝母细胞瘤的结果。在本研究中,我们报告了最终分析结果,该分析纳入了2006年1月至2013年12月期间来自13家医院的153例肝母细胞瘤患者。该队列的6年总生存率和无事件生存率分别为83.3±3.1%和71.0±3.7%。单因素分析显示,女性(P = 0.027)、5岁以下(P = 0.039)、手术完全切除(P = 0.000)、无转移(P = 0.000)以及新辅助化疗后延迟手术(P = 0.000)的患者预后较好。多因素分析显示,男性、5岁及以上、PRETEXT III期或IV期以及手术切除不完全是导致预后不良的一些不利因素。本研究的初步结果表明,按照武汉方案接受治疗的患者与发达国家患者的总生存率和无事件生存率相似。然而,该方案在标准化手术切除(包括肝移植)、完善风险分层和基于风险的化疗方面仍有待进一步优化。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验